Auris Medical Holding AG (NASDAQ:EARS) shares saw an uptick in trading volume on Thursday . 437,681 shares traded hands during mid-day trading, an increase of 353% from the previous session’s volume of 96,678 shares.The stock last traded at $4.45 and had previously closed at $3.95.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Tuesday, July 12th. Leerink Swann reiterated a “buy” rating and issued a $12.00 price target on shares of Auris Medical Holding AG in a report on Wednesday, June 15th. Finally, Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a report on Friday, June 10th.

The stock’s market capitalization is $162.38 million. The firm’s 50 day moving average price is $3.97 and its 200 day moving average price is $3.95.

Auris Medical Holding AG (NASDAQ:EARS) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.04. During the same quarter last year, the business earned ($0.28) earnings per share. Analysts predict that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.